Health Canada approves MedMira’s Multiplo Rapid TP/HIV test for Syphilis and HIV: Halifax, Canada Friday, December 27, 2024, 10:00 Hrs [IST] MedMira Inc. (MedMira), a leading de ...

The test enables healthcare professionals to identify HIV-1/2 and syphilis antibodies from a single finger prick sample.

The quiet resumption of operations at a desalination plant in the Gaza Strip last month marked a small but significant step ...

Medmira (TSE:MIR) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street analysts, ...

HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, ...

Syria's new leaders announced Tuesday that they had reached an agreement with the country's rebel groups on their dissolution ...

Highlights:,MedMira Inc. Reports a Net Loss of CAD 3.33 Million for FY 2024,Clinical Trials for Multiplo® Complete Syphilis Test Underway,Stock Performance Shows Positive 5-Day Growth of 6.25%,MedMira ...

HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter MedMira Inc. has reported progress in expanding its market presence and securing regulatory approvals.

The Company's completed clinical trials showed a sensitivity of 100% for HIV-1 and HIV-2 MedMira's Reveal® G4 HIV-1/2 rapid antibody test achieved a flawless 100% specificity and was reactive in ...

HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. In December 2023, the Company ...

As of 4:30 p.m. GMT+1. Market Open. HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024 ...